🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

404 results for “treatment” Clear

  1. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  2. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  3. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  4. Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study

    Disc Medicine

    colorectal liver metastases

    phase 1 other active

    1 trial

  5. DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    DC-CIK Treatment

    phase 1 other active

    1 trial

  6. First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

    The George Institute

    Relapsed/refractory B-cell aggressive lymphoma

    phase 1 other active

    1 trial

  7. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial

  8. HS-10345 84mg

    Jian Li

    Treatment Resistant Depressive Disorder

    phase 1 small molecule completed

    1 trial

  9. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  10. Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    Pfizer Australia Pty Ltd

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 1 other active

    1 trial

  11. Miricorilant Treatment A

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  12. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  13. Pharmacokinetic study of colistimethate sodium

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

  14. Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer

    Disc Medicine

    Cervical Cancer

    phase 1 other active

    1 trial

  15. Placebo for Treatment A

    Agios Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial

  17. Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial

  18. Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  19. SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  20. SPN-817, Treatment B

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  21. Sativex® (Treatment A)

    Jazz Pharmaceuticals Ireland Limited

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  22. Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

    Lacuna Pharma Pty Ltd

    Severe IgE-mediated food allergy

    phase 1 other active

    1 trial

  23. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fed conditions.

    phase 1 other active

    1 trial

  24. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources